Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
American Journal of Surgery|April 5, 2020
Adequate sentinel node harvest is associated with low false negative rate in breast cancer managed with neoadjuvant chemotherapy and targeted axillary dissectionThomas L Sutton, Nathalie Johnson, Jennifer R GarreauAmerican Journal of Surgery|January 26, 2018
Breast cancer in women under 50: Most are not high riskThomas Sutton, Phil Reilly, Nathalie Johnson, et al.American Journal of Surgery|May 2, 2006
Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulationJennifer R Garreau, Patrick Muller, Rodney Pommier, et al.American Journal of Surgery|January 7, 2019
Atypical ductal hyperplasia: Clinicopathologic factors are not predictive of upgrade after excisional biopsyThomas Sutton, Maryam Farinola, Nathalie Johnson, et al.American Journal of Surgery|September 19, 2006
Side effects of aromatase inhibitors versus tamoxifen: the patients' perspectiveJennifer R Garreau, Tammy Delamelena, Deb Walts, et al.Journal of Surgical Oncology|October 30, 2020
Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survivalThomas L Sutton, Alexander Schlitt, Stuart K Gardiner, et al.American Journal of Surgery|March 24, 2020
Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication ratesThomas L Sutton, Nathalie Johnson, Alexander Schlitt, et al.American Journal of Surgery|June 6, 2022
Variation in adoption of skin and nipple sparing mastectomy: An opportunity to enhance patient outcomesCatherine L Wetzel, Stuart K Gardiner, Nathalie Johnson, et al.American Journal of Surgery|May 3, 2005
Risk counseling and management in patients with lobular carcinoma in situJennifer R Garreau, Joanne Nelson, Regan Look, et al.Journal of Surgical Oncology|August 20, 2021
Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomesCatherine L Wetzel, Thomas L Sutton, Stuart Gardiner, et al.Pageof 2